by James Lyons-Weiler, PhD and Dr. David Brownstein, ©2026
(Feb. 24, 2026) — (NB: I am grateful for Dr. Brownstein’s continuous objectivity on the true status of the science on statins. He raises the bar above rhetoric. Here, he joins me in an earnest attempt to describe precisely why doctors who think statins are generally useful or even useful in most cases of cardiovascular disease think the way they do based on the available studies.-JLW)
This article does not argue that statins lack efficacy in high-risk secondary prevention. It argues that the magnitude of benefit is modest in absolute terms, that safety claims must be comparator-stratified, and that extrapolation into low-risk populations exceeds the evidence base. We stand by these estimates of harm based on RCT-level evidence:
- New-onset diabetes: NNH ~100–200 over 4–5 years (lower with high intensity).
- Mild muscle symptoms: NNH ~100 in RCT data.
- Severe myopathy/rhabdomyolysis: NNH >10,000.
- Liver enzyme elevation: NNH ~100–200.
As always, this is not medical advice. Check with your doctor before starting or stopping any medication. Again, do not start or stop any prescribed medication without consulting with the responsible physician.
-Dr. James Lyons-Weiler (PhD) and David Brownstein, MD
Author: The Statin Disaster, www.drbrownstein.com, Blog: Dr Brownstein’s Holistic Medicine
The claim that statins are safe and broadly life-saving rests on a foundational set of clinical trials and meta-analyses conducted in highly selected, high-risk populations. What followed, however, was a widespread extrapolation of these results to low-risk, diet-optimized, and drug-naïve individuals, in whom no outcome trial has ever been conducted. This article, exclusive to Popular Rationalism, reconstructs what was truly shown in the original trials, exposes how comparators were misused and misrepresented in subsequent analyses, identifies the limits of generalizability to the broader population, and calls for a recalibration of risk-benefit claims based on actual evidence.
What Was Found: The Original Placebo-Controlled Trials
The 4S (Scandinavian Simvastatin Survival Study, Lancet 1994;344:1383-1389) enrolled 4,444 patients aged 35–70 with coronary heart disease (CHD) and baseline total cholesterol 5.5–8.0 mmol/L(213mg/dl-309 mg/dl). Participants were randomized to simvastatin 20–40 mg/day vs placebo. After a median follow-up of 5.4 years, the simvastatin group showed a 30% relative reduction in all-cause mortality (RR 0.70, 95% CI 0.58–0.85), with 256 deaths in the placebo group vs 182 in the treatment group. The absolute risk reduction (ARR) was 1.67% per year.
WOSCOPS (West of Scotland Coronary Prevention Study, N Engl J Med 1995;333:1301-1307) randomized 6,595 men (45–64 years) with hypercholesterolemia (LDL >155 mg/dL) and no prior MI to pravastatin 40 mg or placebo. After 4.9 years, pravastatin reduced the risk of definite MI or CHD death by 31% (relative risk reduction 0.69, 95% CI 0.54–0.87), with an absolute risk reduction of 0.9%/year. Notably, this was a high-LDL, moderate-risk primary prevention group.
The Heart Protection Study (HPS, Lancet 2002;360:7-22) randomized 20,536 high-risk individuals (CHD, other vascular disease, or diabetes) to simvastatin 40 mg vs placebo for 5 years. Statin use reduced major vascular events by 24% (relative risk reduction 0.76, 95% CI 0.72–0.81), and an absolute risk reduction of 5.4% and all-cause mortality reduced by 14% (relative risk) and an absolute risk reduction of 1.8%. This study had consistent effects across subgroups. VERY Importantly, these were not healthy individuals: 16% had prior MI, 33% had diabetes, and 65% were on antihypertensives.
These trials established that statins reduce cardiovascular events in high-risk patients. However, they were conducted in populations with substantial background pharmacotherapy, baseline dyslipidemia, and elevated absolute risk. Furthermore, there was a vast difference between relative risk reduction and absolute risk reduction in these statin studies as well as every other statin study conducted to date.
What They Did NOT Show
None of the foundational trials—4S, WOSCOPS, HPS, or ASCOT—tested statins in individuals with low baseline cardiovascular risk, optimized diet, minimal comorbidities, or absence of other medications. There were no arms comparing statins to intensive lifestyle change, structured low-carbohydrate or low-sugar nutrition, or exercise-only protocols. The populations were not representative of integrative-care patients or healthy middle-aged adults considering statins for marginal LDL elevation. These trials also did not track long-term subclinical harms such as mitochondrial dysfunction, nutrient depletion, coronary calcification, or progressive metabolic disruption. Nor did they stratify outcomes by pre-existing nutritional status, polypharmacy burden, or fitness baseline. Thus, while the trials showed that statins reduce cardiovascular events in high-risk, pharmacologically managed patients, ARR was miniscule from 1-3% in almost every statin study meaning 99-97% arguably received no discernable benefit. Absolute benefit is concentrated in those with the highest baseline risk; in low-risk populations, NNT becomes very large. They also provide no evidentiary basis for prescribing statins to low-risk, health-oriented populations, or people who moved into the low-risk, health-oriented populations—yet it is precisely in this population that prescription rates continue to rise. The result is a dangerous illusion of universality drawn from data that never supported it.
Read the rest here.